Research
Hormonal
DL001 reduces the immunosuppressive effects of mTOR inhibition compared to rapamycin, specifically preserving more T cell and Treg populations.
This study shows that DL001, a selective mTORC1 inhibitor, causes less suppression of T cells and T regulatory cells than standard rapamycin in mice. This suggests that future human applications of selective mTOR inhibitors might have a better safety profile regarding immune function and infection risk, though human trials are needed to confirm this.
GoodSupportsHIGH confidence
In contrast, DL001 had a significantly smaller effect on total T cell and helper T cell numbers, reducing the number of CD3+ cells and CD3+CD4+ cells by 13% and 23%, respectively... rapamycin reduced total CD3+ (T) cell numbers by 40%, and CD3+CD4+ (helper T) cell numbers by 47%.
Why this rating
Clear flow cytometry data showing reduced immune suppression in mice.
Source
A novel rapamycin analog is highly selective for mTORC1 in vivo
Katherine H. Schreiber et al. · Nature Communications · 2019
DOI 10.1038/s41467-019-11174-0
mechanism_onlyCited 197×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The novel rapamycin analog DL001 selectively inhibits mTORC1 in vivo without disrupting glucose or lipid homeostasis, unlike conventional rapamycin which causes metabolic side effects via mTORC2 inhibition.Good
- DL001 effectively suppresses hyperactive mTORC1 signaling in cells lacking a functional TSC (Tuberous Sclerosis Complex), restoring normal gene expression.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →